

118

CASE DB13NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Keith R. Lange
Type or print name

Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
STARLING ET AL.

Art Unit: 1644

Examiner: Haddad, Maher M.

APPLICATION NO: 09/745,605

FILED: DECEMBER 22, 2000

FOR: NOVEL IMMUNOGLOBULIN SUPERFAMILY MEMBERS OF APEX-
1, APEX-2 AND APEX-3 AND USES THEREOF

03 JAN 14 AM 8:30

RECEIVED
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

**DECLARATION OF PRIOR INVENTION IN
THE UNITED STATES TO OVERCOME A REFERENCE UNDER 37 C.F.R. § 1.131**

Sir:

respectively New Zealand and

1. We, Gary C. Starling and Joshua N. Finger, ~~both~~ *52 James Vincent Drive, CLINTON CT 06413* citizens of the United States, residing respectively at ~~11 Galle Court, Lawrenceville, NJ 08648~~ *and* 197 North Union Street, Apt. B, Lambertville, NJ 08530 are joint inventors of the above-identified application.


2. At the time of the invention thereof we were working for Bristol-Myers Squibb Company, assignee of the present application. We submit this declaration to establish completion of the invention set forth in this application in the United States at a date prior to December 9, 1999, i.e. the publication date of WO 99/63088 to Baker et al. (hereinafter the '088 publication), which was cited by the Examiner in an Office Action mailed June 5, 2002.

3. From the documents submitted herewith and as set forth hereinbelow, it can be seen that the invention was completed in the United States before December 9, 1999, the publication date of the '088 publication. Completion of the invention prior to December 9, 1999 is shown by conception and actual reduction to practice of the invention as evidenced by the cloning and sequencing of the APEX-1 gene (hereinafter "APEX-1"), which is also referred to in Exhibit A as DCS4.
4. To establish conception and reduction to practice, i.e. completion of the invention at a date prior to December 9, 1999, the following documents are submitted as evidence:
 - a. Bristol-Myers Squibb Notebook No. 42973 assigned and completed prior to December 9, 1999 (Exhibit A), pages 42973-103 through 42973-106, 42973-112 through 42973-114, 42973-127 through 42973-129 and page 42973-158. These pages show the full-length cloning of APEX-1 and set forth the nucleotide and amino acid sequences of APEX-1, which correspond to SEQ ID NOS. 1 and 4, respectively, in the present application. The full length cDNA sequence and amino acid translation of APEX-1 is shown on page 42973-158. These notebook records evidence conception and actual reduction to practice of the complete invention prior to December 9, 1999.
5. The materials submitted herewith establish that the invention as claimed was completed, i.e. conceived and reduced to practice, at a date prior to December 9, 1999, the publication date of the '088 publication.

6. This declaration is submitted in a response to a non-Final Office Action dated June 5, 2002 and is therefore believed to be timely filed.

7. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DATED: 12/09/02



Gary C. Starling

DATED: _____

Joshua N. Finger

RECEIVED
TECH CENTER 1600/2900
CASE DB13NP

03 JAN 14 AM 8:31

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Keith R. Lange

Type or print name

Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
STARLING ET AL.

Art Unit: 1644

Examiner: Haddad, Maher M.

APPLICATION NO: 09/745,605

FILED: DECEMBER 22, 2000

FOR: NOVEL IMMUNOGLOBULIN SUPERFAMILY MEMBERS OF APEX-
1, APEX-2 AND APEX-3 AND USES THEREOF

Assistant Commissioner for Patents
Washington, D.C. 20231

**DECLARATION OF PRIOR INVENTION IN
THE UNITED STATES TO OVERCOME A REFERENCE UNDER 37 C.F.R. § 1.131**

Sir:

1. We, Gary C. Starling and Joshua N. Finger, both citizens of the United States, residing respectively at 11 Gallo Court, Lawrenceville, NJ 08648 and 197 North Union Street, Apt. B, Lambertville, NJ 08530 are joint inventors of the above-identified application.
2. At the time of the invention thereof we were working for Bristol-Myers Squibb Company, assignee of the present application. We submit this declaration to establish completion of the invention set forth in this application in the United States at a date prior to December 9, 1999, i.e. the publication date of WO 99/63088 to Baker et al. (hereinafter the '088 publication), which was cited by the Examiner in an Office Action mailed June 5, 2002.

3. From the documents submitted herewith and as set forth hereinbelow, it can be seen that the invention was completed in the United States before December 9, 1999, the publication date of the '088 publication. Completion of the invention prior to December 9, 1999 is shown by conception and actual reduction to practice of the invention as evidenced by the cloning and sequencing of the APEX-1 gene (hereinafter "APEX-1"), which is also referred to in Exhibit A as DCS4.
4. To establish conception and reduction to practice, i.e. completion of the invention at a date prior to December 9, 1999, the following documents are submitted as evidence:
 - a. Bristol-Myers Squibb Notebook No. 42973 assigned and completed prior to December 9, 1999 (Exhibit A), pages 42973-103 through 42973-106, 42973-112 through 42973-114, 42973-127 through 42973-129 and page 42973-158. These pages show the full-length cloning of APEX-1 and set forth the nucleotide and amino acid sequences of APEX-1, which correspond to SEQ ID NOS. 1 and 4, respectively, in the present application. The full length cDNA sequence and amino acid translation of APEX-1 is shown on page 42973-158. These notebook records evidence conception and actual reduction to practice of the complete invention prior to December 9, 1999.
5. The materials submitted herewith establish that the invention as claimed was completed, i.e. conceived and reduced to practice, at a date prior to December 9, 1999, the publication date of the '088 publication.

6. This declaration is submitted in a response to a non-Final Office Action dated June 5, 2002 and is therefore believed to be timely filed.

7. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DATED: _____


Gary C. Starling

DATED: 12-17-02


Joshua N. Finger

CD2 Subfamily Extracellular domains

CD2 CD58 CD48 SLAM APEX-1 APEX-2 APEX-3



• = potential N-linked glycosylation sites

FIGURE 1

GGAAGTGGCTTCATTTTCAGTGGCTGACTTCCAGAGAGCAAT 41
 ATGGCTGGTTCCCCAACATGCCTCACCTCATCTATATCCTTTGGCAGCTCACAGGGTCA 101
 M A G S P T C L T L I Y I L W Q L T G S 20
 GCAGCCTCTGGACCCGTGAAGAGCTGGTGGTTCCGTTGGTGGGGCCGTGACTTTCCCC 161
 A A S G P V K E L V G S V G G A V T F P 40
 CTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTT 221
 L K S K V K Q V D S I V W T F N T T P L 60
 GTCACCATACAGCCAGAAGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGA 281
 V T I Q P E G G T I I V T Q N R N R E R 80
 GTAGACTTCCCAGATGGAGGCTACTCCCTGAAGCTCAGCAAACCTGAAGAAGAATGACTCA 341
 V D F P D G G Y S L K L S K L K K N D S 100
 GGGATCTACTATGTGGGGATATACAGCTCATCACTCCAGCAGCCCTCCACCCAGGAGTAC 401
 G I Y Y V G I Y S S S L Q Q P S T Q E Y 120
 GTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGTCACCATGGGTCTGCAGAGCAAT 461
 V L H V Y E H L S K P K V T M G L Q S N 140
 AAGAATGGCCTGTGTGACCAATCTGACATGCTGCATGGAACATGGGGAAGAGGATGTG 521
 K N G T C V T N L T C C M E H G E E D V 160
 ATTTATACCTGGAAGGCCCTGGGGCAAGCAGCCAAATGAGTCCCATATGGGTCCATCCTC 581
 I Y T W K A L G Q A A N E S H N G S I L 180
 CCCATCTCCTGGAGATGGGGAGAAAGTGATATGACCTTCATCTGCGTTGCCAGGAACCTT 641
 P I S W R W G E S D M T F I C V A R N P 200
 GTCAGCAGAACTTCTCAAGCCCCATCCTTGCCAGGAAGCTCTGTGAAGGTGCTGCTGAT 701
 V S R N E S S P I L A R K L C E G A A D 220
 GACCCAGATTCTCTCATGGTCTCTGTGTCTCTGTTGGTGGCCCTCTGCTCAGTCTC 761
 D P D S S M V L L C L L L V P L L L S L 240
 TTTGTAAGTGGGCTATTCTTTGGTTTCTGAAGAGAGAGACAAGAAGAGTACATTGAA 821
F V L G L F L W F L K R E R Q E E Y I E 260
 GAGAAGAAGAGAGTGGACATTTGTGGGAAACTCCTAACATATGCCCCATTCTGGAGAG 881
 E K K R V D I C R E T P N I C P H S G E 280
 AACACAGAGTACGACACAATCCCTCACACTAATAGAACAATCCTAAAGGAAGATCCAGCA 941
 N T E Y D T I P H T N R T I L K E D P A 300
 AATACGGTTTACTCCACTGTGGAATACCGAAAAAGATGGAATCCCCACTCACTGCTC 1001
 N T V Y S T V E I P K K M E N P H S L L 320
 ACGATGCCAGACACACCAAGGCTATTGCTATGAGAATGTTATCTAGACAGCAGTGCAC 1061
 T M P D T P R L F A Y E N V I * 335
 TCCCTTAAGTCTCTGCTCAAAAAAAAAACAATTCTCGGCCAAAAGAAAACAATCAGAAGA 1121
 ATTCAGTATTGACTAGAAACATCAAGGAAGAATGAAGAACGTTGACTTTTTCAGGA 1181
 TAAATTATCTCTGATGCTTCTTTAGATTTAAGAGTTCGTAATTCATCCACTGCTGAGAA 1241
 ATCTCCTCAAAACCCAGAAGGTTTAATCACTTCATCCAAAATGGGATTGTGAATGTGAG 1301
 CAAACCATAAAAAAGTGCTTAGAAGTATTCCTATAGAAATGTAATGCAAGGTCACACA 1361
 TATTAATGACAGCCTGTTGTATTAATGATGGCTCCAGGTCAGTGTCTGGAGTTTCATCC 1421
 ATCCCAGGGCTTGATGTCAGGATTATACCAAGAGTCTTGCTACCAGGAGGGCAAGAAGA 1481
 CCAAAACAGACAGACAAGTCCAGCAGAAGCAGATGCACCTGACAAAAATGGATGTATTAA 1541
 TTGGCTCTATAAATATGTGCCAGCACTATGCTGAGCTTACACTAATGGTCAGACGTG 1601
 CTGTCTGCCCTCATGAATTTGGCTCCAAATGAATGAACACTTTTCATGAGCAGTTGTAGC 1661
 AGGCTGACCACAGATCCCAGAGGGCCAGGTGTGGATCCACAGGACTTGAAGGTCAAAG 1721
 TTCACAAAGATGAAGAATCAGGGTAGCTGACCATGTTTGGCAGATACTATAATGGAGACA 1781
 CAGAAGTGTGCATGGCCCAAGGACAAGGACCTCCAGCCAGGCTTCATTATGCACTTGTG 1841
 CTGCAAAAGAAAAGTCTAGGTTTAAAGGCTGTGCCAGAACCCATCCCAATAAAGAGACCG 1901
 AGTCTGAAGTCACATGTAAATCTAGTGTAGGAGACTTGGAGTCAGGCAGTGAAGTGGT 1961
 GGGGCACGGGGGAGTGGGTACTTGTAAACCTTTAAAGATGGTTAATTCATTCAATAGA 2021
 TATTATTAAAGAACCTACTATGCGGCCCGGCATGGTGGCTCACACCTGTAATCCAGCAC 2081
 TTTGGGAGGCCAAGGTGGGTGCTGAGGTGAGGAGTTCAGACCCAGCCTGGCCAA 2141
 CATGGTGAAACCCATCTCTACTAAAGATCAAATTTGCTGAGCGTGGTGGTGTGCACCT 2201

FIGURE 2A

GTATCCCAGCTACTCGAGAGGCCAAGGCATGAGAATCGCTTGAACCTGGAGGTGAGGTTG 2261
CAGTGAGCTGAGATGGCACCCTGCACTCCGGCCTAGGCAACGAGAGCAAACTCCAATA 2321
CAACAAACAAACAAACACCTGTGCTAGGTCACTCTGGCACGTAAGATGAACATCCCTAC 2381
CAACACAGAGCTCACCATCTCTTATACTTAAGTAAAAACATGGGGAAGGGGAAAGGGGA 2441
ATGGCTGCTTTTGATATGTTCCCTGACGCATATCTTGAATGGAGACCTCCCTACCAAGTG 2501
ATGAAAGTGTTGAAAACTTAATAACAAATGCTTGTGGGCAAGAATGGGATTGAGGATT 2561
ATCTTCTCTCAGAAAGGCATTGTGAAGGAATTGAGCCAGATCTCTCTCCCTACTGCAAAA 2621
CCCTATTGTAGTAAAAAGTCTTTTACTATCTTAATAAACAGATATTGTGAGATTCA 2681
CATAAAAAAAAAAAAAAAAAAAAA

FIGURE 2B

1 CCATCCTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTTCAAGTTCCA
 61 CGTTCCCTACTGCTAAGAGTCTTAGCTTACAAAAGATATTCTTGTAAGCCAAGTGTGAAG
 121 TTAATCAGGACAACCAAAGGTTTGCTAACATAGAGGAAGAGCTCTCATCAATAGGGGAAC
 181 AGAAAGTCTCAGCGACAAGCTTATGAAAGAATGGCTGTCTCAAGGGCTCCAACACCCGAC
 M A V S R A P T P D
 241 TCCGCCTGTCAGAGGATGGTCTGGCTCTTTCCACTTGTCTTCTGCCTCGGCTCAGGGAGT
 S A C Q R M V W L F P L V F C L G S G S
 301 GAAGTTTCACAGAGCAGCTCAGACCCCCAGCTAATGAATGGCGTTCTAGGAGAGTCTGCA
 E V S Q S S S D P Q L M N G V L G E S A
 361 GTTCTTCCTCTAAAGCTTCCTGCAGGAAGATAGCCAATATCATCATCTGGAATTATGAA
 V L P L K L P A G K I A N I I I W N Y E
 421 TGGGAAGCGTCACAAGTCACTGCCCTCGTTATCAACCTAAGTAATCCTGAAAGTCCACAA
 W E A S Q V T A L V I N L S N P E S P Q
 481 ATCATGAACACTGATGTAAAGAAGAGACTGAACATCACCCAGTCCTACTCCCTGCAAATC
 I M N T D V K K R L N I T Q S Y S L Q I
 541 AGCAACCTTACCATGGCAGACACAGGATCATACACTGCGCAGATAACCACAAAGGACTCT
 S N L T M A D T G S Y T A Q I T T K D S
 601 GAAGTGATCACCTTCAAATATATTCTGAGGGTCTTTGAACGATTGGGTAACCTTAGAAACT
 E V I T F K' Y I L R V F E R L G N L E T

FIGURE 3A

661 ACCAACTATACTCTCCTGCTAGAGAATGGGACCTGCCAGATACACCTGGCCTGTGTTTTG
 T N Y T L L L E N G T C Q I H L A C V L
 721 AAGAATCAAAGTCAAAGTGTCTCAGTTGAGTGGCAAGCCACAGGAAACATCTCTTTAGGA
 K N Q S Q T V S V E W Q A T G N I S L G
 781 GGACCAAATGTCACTATCTTTTGGGACCCGAGGAATTCTGGTGACCAGACTTACGTCTGC
 G P N V T I F W D P R N S G D Q T Y V C
 841 AGAGCCAAGAATGCTGTCAGCAATTTGTCTGCTCTGTTTCGACCCAGAGTCTCTGCAAA
 R A K N A V S N L S V S V S T Q S L C K
 901 GGGGTTCTAACTAATCCACCCTGGAATGCAGTATGGTTTATGACTACAATTTCAATAATC
 G V L T N P P W N A V W F M T T I S I I
 961 AGTGCAGTCATACTCATCTTTGTGTGCTGGAGCATACTGTTTGAAGAGAAGAGGTTCT
 S A V I L I F V C W S I H V W K R R G S
 1021 CTTCTTTGACTAGCCAACATCCAGAGTCTCCAGAGCACAGATGGCCCAGGCTCTCCA
 L P L T S Q H P E S S Q S T D G P G S P
 1081 GGGAACACTGTGTATGCACAAGTCACTCGTCCAATGCAGGAAATGAAATCCCAAAACCT
 G N T V Y A Q V T R P M Q E M K I P K P
 1141 ATCAAAAATGACTCCATGACAATTTACTCCATAGTTAATCATTCCAGAGAGGAAACAGTG
 I K N D S M T I Y S I V N H S R E E T V
 1201 GCTTTAACCGGCTATAACCAACCCATTACCCTGAAGGTTAACTTTAATCAACTATAAC
 A L T G Y N Q P I T L K V N T L I N Y N
 1261 TCCTGAAGGAAGAGCACTGCAGTGACTTGAGGAAATTAAACAATGCTGTCACCACAGCTC
 S *

FIGURE 3B

1321 TGGCTTAGATTAATGAAGTCAGCATCTCTGGAGATTGAGCGCTGCCATTTCATTGTTCA
-----+-----+-----+-----+-----+
1381 AACGCTTTCTAGGTGGTATGGTGAGATGCCAGAGGGCTAAGGGCCATTATAGCAGGGTAG
-----+-----+-----+-----+-----+
1441 TTTGACTAGGAATACATAAGATAGAAAGCCTAGAATCGTATCATTGAAAGGGACAATGGA
-----+-----+-----+-----+-----+
1501 CCTAAGAGAAGTGGAATAAAATTGTGTCACACAAAAAAAAAAAAAAAAAAAAAAAAAG
-----+-----+-----+-----+-----+
CTTGT
1561 ----- 1565

FIGURE 3C

Apex-3 nucleotide with translation

1 GAATTCGAATTCGGGACTTTCCAGAAGGACCACAGCTCCTCCCGTGCATCCACTCGGCCT
 -----+-----+-----+-----+-----+-----+-----+

 61 GGGAGGTTCTGGATTTTGGCTGTCGAGGGAGTTTGCCTGCCTCTCCAGAGAAAGATGGTC
 -----+-----+-----+-----+-----+-----+-----+
 M V

 121 ATGAGGCCCCCTGTGGAGTCTGCTTCTCTGGGAAGCCCTACTTCCCATTACAGTTACTGGT
 -----+-----+-----+-----+-----+-----+-----+
 M R P L W S L L L W E A L L P I T V T G

 181 GCCCAAGTGCTGAGCAAAGTCGGGGGCTCGGTGCTGCTGGTGGCAGCGCTCCCCCTGGC
 -----+-----+-----+-----+-----+-----+-----+
 A Q V L S K V G G S V L L V A A R P P G

 241 TTCCAAGTCCGTGAGGCTATCTGGCGATCTCTCTGGCCTTCAGAAGAGCTCCTGGCCACG
 -----+-----+-----+-----+-----+-----+-----+
 F Q V R E A I W R S L W P S E E L L A T

 301 TTTTCCGAGGCTCCCTGGAGACTCTGTACCATTCCCGCTTCCTGGGCGGAGCCCAGCTA
 -----+-----+-----+-----+-----+-----+-----+
 F F R G S L E T L Y H S R F L G R A Q L

 361 CACAGCAACCTCAGCCTGGAGCTCGGGCCGCTGGAGTCTGGAGACAGCGGCAACTTCTCC
 -----+-----+-----+-----+-----+-----+-----+
 H S N L S L E L G P L E S G D S G N F S

 421 GTGTTGATGGTGGACACAAGGGGCCAGCCCTGGACCCAGACCCTCCAGCTCAAGGTGTAC
 -----+-----+-----+-----+-----+-----+-----+
 V L M V D T R G Q P W T Q T L Q L K V Y

 481 GATGCAGTGCCCAGGCCCGTGGTACAAGTGTTTCATTGCTGTAGAAAGGGATGCTCAGCCC
 -----+-----+-----+-----+-----+-----+-----+
 D A V P R P V V Q V F I A V E R D A Q P

 541 TCCAAGACCTGCCAGGTTTTCTTGCTCTGTTGGGCCCCCAACATCAGCGAAATAACCTAT
 -----+-----+-----+-----+-----+-----+-----+
 S K T C Q V F L S C W A P N I S E I T Y

FIGURE 4A

601 AGCTGGCGACGGGAGACAACCATGGACTTTGGTATGGAACCACACAGCCTCTTCACAGAC
 S W R R E T T M D F G M E P H S L F T D
 661 GGACAGGTGCTGAGCATTTCCTGGGACCAGGAGACAGAGATGTGGCCTATTCCTGCATT
 G Q V L S I S L G P G D R D V A Y S C I
 721 GTCTCCAACCCTGTCAGCTGGGACTTGGCCACAGTCACGCCCTGGGATAGCTGTCATCAT
 V S N P V S W D L A T V T P W D S C H H
 781 GAGGCAGCACCAGGGAAGGCCTCCTACAAAGATGTGCTGCTGGTGGTGGTGCCTGTCTCG
 E A A P G K A S Y K D V L L V V V P V S
 841 CTGCTCCTGATGCTGGTTACTCTCTTCTCTGCCTGGCACTGGTGGCCCTGCTCAGGGAAA
 L L L M L V T L F S A W H W C P C S G K
 901 AAGAAAAAGGATGTCCATGCTGACAGAGTGGGTCCAGAGACAGAGAACCCCTTGTGCAG
 K K K D V H A D R V G P E T E N P L V Q
 961 GATCTGCCATAAAGGACAATATGAACTGATGCCTGGACTATCAGTAACCCCACTGCACAG
 D L P *
 1021 GCACACGATGCTCTGGGACATAACTGGTGCCTGGAAATCACCATGGTCTCATATCTCCC
 1081 ATGGGAATCCTGTCCTGCCTCGAAGGAGCAGCCTGGGCAGCCATCACACCAGGAGACAG
 1141 GAAGCACCAGCACGTTTCACACCTCCCCCTTCCCTCTCCCATCTTCTCATATCCTGGCTC
 1201 TTCTCTGGGCAAGATGAGCCAAGCAGAACATTCCATCCAGGACACTGGAAGTTCTCCAGG

FIGURE 4B

1261 ATCCAGATCCATGGGGACATTAATAGTCCAAGGCATTCCCTCCCCCACCCTATTTCATAA
-----+-----+-----+-----+-----+-----+-----+
1321 AGTATTAACCAACTGGCACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
-----+-----+-----+-----+-----+-----+-----+
1381 AAAAAAAAAAAAAAAGGGCGGCCGCCCG
-----+-----+-----+-----+-----+-----+-----+ 1408

FIGURE 4C

FIGURE 5**FIGURE 5**


M S K N Q K Q G S M L V S *
 A G L L I Y I G N T P T R E
 V S P S S I H P L T L R E
 S E A N N L L N S I T P E
 R V G P L R A V S S M T
 A S K E T V C T S I Q Q V
 P Q I S M F V I V I H E A
 T S A P A E L F S S P M L
 P S N Q D R K W T A E K T
 D S I I T L N D Q V S I G
 S D I M G G Q P S I S P Y
 A P I N S N S R R L Q K N
 C Q W T Y L Q N C I S P Q
 Q L N D T E T S K F T I P
 R M Y V A T V G G V D K I
 M N E K Q T S D V C G N T
 V G W K I N V Q L W P D L
 W V E R T Y E T T S G S K
 L L A L T T W Y N I S M V
 F G S N K L Q V P H P T N
 P E Q I D L A C P V G I T
 L S V T S L T R W W N Y L
 V A T Q E E G A N K T S I
 F V A S V N N K A R V I N
 C L L Y I G I N V R Y V Y
 L P V S T T S A W G A N N
 G L I L F C L V F S Q H S

FIGURE 6

M	V	M	R	P	L	W	S	L	L	L	W	E	A	L	L	P	I	T	V	T	G
A	Q	V	L	S	K	V	G	G	S	W	L	L	V	E	A	A	P	F	G	F	Q
V	R	E	T	I	W	R	S	L	S	F	S	E	E	R	Q	H	T	N	F	R	S
S	L	E	P	L	H	S	S	D	R	S	G	R	A	F	V	M	S	D	S	R	Q
E	P	G	T	Q	E	L	G	L	Q	K	A	D	S	T	Q	P	V	V	T	W	E
Q	I	W	V	E	T	D	Q	S	V	P	Y	E	A	C	T	L	D	G	C	M	D
F	N	A	S	T	R	T	Q	V	A	W	R	S	L	T	G	P	P	R	V	D	P
P	S	I	F	E	I	G	P	V	F	S	I	E	A	T	L	V	V	G	S	V	K
H	S	A	A	T	D	N	K	A	S	S	D	L	V	W	C	L	G	D	P	K	P
L	L	E	M	V	S	G	L	F	G	P	K	H	N	C	P	L	Q	D	L	P	*
K	D	V	H	A	D	R	V	G	P	E	T	E									

FIGURE 7

A



B




FIGURE 8

Tissue Distribution of Apex1 Expression




FIGURE 9

Peptides in APEX-1Ig

1 **MAGSPTCLTL** **IYILWQLTGS** **AASGPVKELV** GSVGGAVTFP LKSKVKQVDS
51 IVWTFNTTPL VTIQPEGGTI IVTQNRNRER VDFPDGGYSL KLSKLKKNDS
101 GIYYVGIYSS SLQQPSTQEY VLHVEHLSK PKVTMGLQSN KNGTCVTNLT
151 CCMEHGEEDV IYTWKALGQA ANESHNGSIL PISWRWGESD MTFICVARNP
201 VSRNFSSPIL ARKLCEGAAD DPDSS HP humanIgG1 H-CH2-CH3

Bold- Predicted signal sequence, which will be cleaved in mature protein HP - junction sequence resulting from the BamH1 enzyme site.

FIGURE 10

Peptides in APEX-2mIg

1 **MAVSRAPTPD** **SACQRMVWLF** **PLVFCLGSGS** EVSQSSSDPQ LMNGVLGESA
51 VLPLKLPAGK IANIIIWNYE WEASQVTALV INLSNPESPQ IMNTDVKKRL
101 NITQSYSLQI SNLTMADTGS YTAQITTKDS EVITFKYILR VFERLGNLET
151 TNYTLLLENG TCQIHLACVL KNQSQTVSVE WQATGNISLG GPNVTIFWDP
201 RNSGDQTYVC RAKNAVSNLS VSVSTQSLCK GVLTNPPW HP - murine
IgG2a H-Ch2-CH3

Bold- Predicted signal sequence, which will be cleaved in the mature protein HP - junction sequence resulting from the BamH1 enzyme site.

FIGURE 11

Apex-2mlg

Apex-1lg




FIGURE 12





FIGURE 13

Apex1 Antibody Panel

Reduced

13 30 31 34 35 36 40 66 67 68 71 73



Non reduced

13 30 31 34 35 36 40 66 67 68 69 71 73



FIGURE 14

FLAG-APEX-1

MPMGSLOPLATLYLLGMLVASCLG**DYKDDDDK****SGPVKELVGSVGGAVTFP**
LKSKVKQVDSIVWTFNTTPLVTIQPEGGTIIIVTQNRNRERVDFPDGGYSLKLSKLKKNDS
GIYYVGIYSSSLQQPSTQEYVLHVYEHLSKPKVTMGLQSNKNGTCVTNLTCCMEHGEEVD
IYTWKALGQAANESHNGSILPISWRWGESDMTFICVARNPVSRNFSSPILARKLCEGAAD
DPDSSMVLLCLLLVPLLLSLFVLGLFLWFLKRERQEEYIEKKRVDICRETPNICPHSGE
NTEYDTIPHTNRTILKEDPANTVYSTVEIPKKMENPHSLLTMPDTPRLFAYENVI*

MPMGSLOPLATLYLLGMLVASCLG sequence from human CD5 signal peptide,
DYKDDDDK is the FLAG peptide

FIGURE 15

FLAG-APEX-2

MPMGSLQPLATLYLLGLVASCLG**DYKDDDDK**SEVSQSSSDPQLMNGVLGESA
VLPLKLPAGKIANIIWNYEWEASQVTALVINLSNPESPQIMNTDVKKRLNITQSYSLQI
SNLTMA DTGSYTAQITTKDSEVITFKYILRVFERLGNLETTNYTLLLENGTCQIHLACVL
KNQSQTVSVEWQATGNISLGGPNVTIFWDPRNSGDQTYVCRAKNAVSNLSVSVSTQSLCK
GVLTNPPWNAVWFMTTISIISAVILIFVCWSIHVWKRRGSLPLTSQHPESSQSTDGPGSP
GNTVYAQVTRPMQEMKIPKPIKNSMTIYSIVNHSREETVALTGYNQFITLKVNTLINYS*

MPMGSLQPLATLYLLGLVASCLG sequence from human CD5 signal peptide,
DYKDDDDK is the FLAG peptide

FIGURE 16